|

Nivolumab & Ipilimumab Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since June 2026

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Vivace Therapeutics, Inc1
  • The First Affiliated Hospital of Guangzhou Medical University1
  • Inge Marie Svane1
  • Hildur Helgadottir1

Indications

  • Cancer4
  • Lung Cancer - Non Small Cell1
  • Malignant Melanoma Stage III1
  • Mesothelioma1
  • Uveal Melanoma1

Other3 trials

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Phase 1
Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)
Phase 2
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
Phase 3

San Francisco, California1 trial

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

UCSF Helen Diller Family Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.